精准操控与高效分离纳米颗粒，一直是生物技术领域的关键瓶颈。为攻克这一难题，芬兰奥卢大学科学 家开发出一种全新的纳米颗粒分离与纯化方法，显著提升了对合成微粒及细胞分泌的纳米级囊泡的分离 纯度。该技术在血液分析、癌症早期诊断、细胞间通信及纳米医学等领域具有广阔应用前景。相关成果 发表于新一期《分析化学》杂志。 团队表示，现有分离技术往往效率低、操作复杂或稳定性差。而新方法仅需常规微通道，即可实现对纳 米颗粒的高效分选。此前，这类尺寸颗粒的分离依赖极易堵塞的纳米通道，且需高压驱动，难以规模 化。相比之下，新技术更快速、精确，且易于放大应用。 实验表明，新方法将聚苯乙烯标准颗粒的分离纯度提升了30%至50%。这类模型颗粒因尺寸均一、形貌 可控、表面性质稳定，广泛用于微流控技术评估。更为重要的是，团队还将癌细胞分泌囊泡的纯度提高 了20%以上，在极小尺度上实现了显著突破。 （文章来源：科技日报） 纳米尺度是生命活动的重要舞台，许多生物过程都发生在这一级别。从体液中提取的细胞外囊泡，如同 身体的"分子信使"，能反映疾病的早期信号。然而，若无法有效去除杂质，这些珍贵信息便可能被掩 盖。因此，发展一种高效、温和且可靠的纯化手 ...

Core Viewpoint - The recent developments in Hong Kong's economic and financial landscape have garnered significant attention, with a notable increase in IPO activities and GDP growth projected for 2025, indicating a robust recovery and expansion trend since 2021 [2][3]. Group 1: IPO and Market Dynamics - In 2025, Hong Kong is expected to witness 119 IPOs, with a substantial increase in financing, leading the global market [2]. - The Hong Kong stock market has seen a record net inflow of southbound capital, reaching 1,404.84 billion HKD in 2025, marking a historical high since the launch of the Stock Connect program [2]. - The introduction of new IPO regulations by the Hong Kong Stock Exchange in August 2025 has improved the pricing and allocation mechanisms for new shares, while lowering the listing thresholds for "A+H" issuers [2][3]. Group 2: Capital Inflows and International Participation - Domestic capital is actively participating in the Hong Kong stock market for cross-border asset allocation, contributing to a cumulative net inflow of over 5.1 trillion HKD since the Stock Connect's inception [2]. - International capital is increasingly entering the Hong Kong market, driven by a weaker US dollar and global liquidity conditions, seeking safe returns [2][3]. - The majority of new companies established in Hong Kong in 2025 are engaged in import-export trade, wholesale, and retail, reflecting Hong Kong's status as an international trade and financial hub [4]. Group 3: Technological and Structural Developments - The listing rules for unprofitable biotech companies and specialized technology firms in Hong Kong have encouraged the growth of high-tech enterprises, leading to market valuation premiums [3]. - The Hong Kong government is prioritizing the development of an international innovation and technology center, supported by national policies aimed at enhancing technological self-reliance and productivity [5]. - The synergy between technology and finance is expected to drive structural upgrades in Hong Kong's economy, enhancing its competitiveness as an international financial center [5]. Group 4: Future Development Focus - Future national development priorities include promoting supply-side structural reforms, deepening demand-side reforms, and expanding high-level openness [6]. - Hong Kong is positioned to play a crucial role in enhancing national competitiveness in supply chains and participating in the Greater Bay Area market development [6]. - To achieve these goals, Hong Kong must strengthen its hard and soft power across various dimensions, including economic, industrial, and technological capabilities [6].

听上去很魔幻，其实原理并不玄学。 黄金，还能不能囤？ 这个原本属于投资圈的老问题，最近被一条来自欧洲的科研消息，再次推到了台前：人造黄金，似乎真的又向现实靠近了一步。 事情发生在欧洲核子研究中心。科研人员在大型强子对撞机第二阶段运行中发现：高速铅原子在极端条件下发生碰撞时，会短暂生成金原子。论文中给出的 数据很明确：在一次实验过程中，至少产生了860亿个金原子。 换算一下，相当于每秒就"造"出8.9万个金原子。 可即便如此，这项成果依然在科研圈引发了不小的震动。 从原子结构来看，金的原子核含有79个质子，而铅的原子核里有82个。在极高能量条件下，只要从铅核中剥离3个质子及对应的中子组合，元素身份就完成 了转换——从铅，变成了金。这不是炼金术，而是标准的核物理过程。 这些金原子只存在于亚原子尺度，总质量约29皮克，连世界中的一粒尘埃都算不上。更现实的是，它们在诞生瞬间便会撞击装置内壁，生命周期短到不足十 亿分之一秒。别说铸成金条、打成首饰，连"保存"本身都谈不上。 原因不在于"现在能不能造黄金"，而在未来。因为中-国的环形正负电子对撞机（CEPC），加速器与探测器的整体方案已经完成设计。方向一旦明确，资源 一旦 ...

Core Insights - The event highlighted the "Top Ten Technological Advances in Inner Mongolia for 2025," showcasing the region's commitment to technological self-reliance and innovation in various industries [25] Group 1: Technological Innovations - The world's first zero-carbon airport has been completed, utilizing a CO2 integrated energy system [3] - The first haploid stem cells for cattle and sheep have been successfully cultivated, reducing breeding cycles to 12 months and increasing efficiency by 95% [5] - The world's first high-voltage hybrid converter has been developed, enhancing the stability and efficiency of ultra-high voltage transmission systems [9] Group 2: Industrial Developments - The largest coal-to-olefins project globally has been launched, with all core equipment developed domestically, achieving international standards [11] - The first 720V solid-state sodium salt battery has been developed, marking a significant advancement in the energy storage sector [13] - A breakthrough in 5N high-purity aluminum production technology has been achieved, filling a domestic production gap [16] Group 3: Green Technology and Sustainability - A new amino acid production technology using synthetic biology has been successfully implemented, promoting green manufacturing in the bio-fermentation industry [18] - An innovative alkaline electrolyzer has been developed to adapt to wide power fluctuations, supporting hydrogen production and renewable energy integration [20] - A complete set of manufacturing technology for rare earth permanent magnet materials has been developed, improving utilization rates by over 20% [22] Group 4: Chemical and Material Advancements - The highest grade of wet electronic-grade hydrochloric acid has achieved mass production, breaking foreign monopolies in high-purity chemicals [24]

来源：深圳特区报 2月9日，深圳市第七届人民代表大会第七次会议开幕，市长覃伟中代表市政府向大会作政府工作 报告。报告明确了"十五五"时期深圳经济社会发展的主要目标：地区生产总值超过5万亿元。在十 五五"开局之年，深圳提出了5%的GDP预期增速目标，并对全年重点工作作出具体部署。 会上，深圳市市长覃伟中表示，健全与企业全生命周期更相适应的多元化、接力式科技金融服务体 系，壮大耐心资本、长期资本， 加快形成各类创新创业和产业投资基金数量超万家、总规模超万 亿元的"双万基金"格局。 这是深圳两会首次提出"双万基金"格局。 此外，会议还在创新策源、关键核心技术攻关、人才等方面做出谋划，提出加快建设清华大学深圳 国际研究生院（二期）、香港中文大学（深圳）医学院、电子科技大学（深圳）高等研究院等项 目，开展集成电路、工业母机、高端仪器、基础软件、先进材料、生物制造等领域重点产业研发项 目150个以上，今年将推动全社会研发投入增长10%以上，继续组织"百万英才汇南粤"深圳行动 计划，优化实施"孔雀团队"项目，吸引集聚集成电路、人工智能、生物科技、量子科技等重点领 域高层次科技创新人才。 热文： 谁押中了沐曦股份？ 荐读： ...

Core Insights - The biopharmaceutical ETF (512290) rose over 1% on February 10, with a net inflow of over 500 million yuan in the past 20 days, driven by significant BD and technological advancements [1] Industry Summary - The 2026 JPM Healthcare Conference showcased numerous Chinese pharmaceutical companies presenting their latest research achievements and progress, alongside a surge in large BD deals and active collaborations with multinational corporations (MNCs) [1] - The development of brain-computer interfaces and AI applications is thriving, with consumer-oriented stocks expected to benefit from domestic demand recovery [1] - The industry faces several risks, including geopolitical risks overseas, potential product development failures, increased pricing pressure from expanded centralized procurement, intense competition leading to price declines, and significant rises in raw material costs [1] - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services from the Shanghai and Shenzhen markets to reflect the overall performance of related securities [1]

对此，上海百悦律师事务所牛彬律师表示，亚辉龙因涉嫌信息披露违法违规被证监会立案，受损投资者 可依法索赔。暂定：于2026年2月7日之前买入亚辉龙股票，且在2026年2月8日之后卖出或继续持有该股 票的亏损投资者，符合初步索赔条件。 初步索赔范围： 在上市后至2026年2月7日期间买入亚辉龙（688575）股票，并在2026年2月8日收 盘时仍持有或此后卖出的受损投资者。（最终索赔条件以法院生效判决认定为准）（亚辉龙维权入口） 登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 2026年2月6日，深圳市亚辉龙（维权）生物科技股份有限公司（证券简称：亚辉龙，证券代码： 688575）发布《关于收到中国证券监督管理委员会立案告知书的公告》。公告显示：公司于2026年2月6 日收到中国证监会下发的《立案告知书》（编号：证监立案字00720262号）。根据《立案告知书》，因 涉嫌信息披露违法违规，根据《中华人民 ...

本轮融资将主要用于三大方向：加速新一代产品的研发、深化全球化市场布局，并加快顶尖人才的引进。超维景将通 过深化"高端科学仪器+脑机"的双轮驱动战略，进一步巩固技术壁垒，推动高时空分辨率神经观测技术在临床和脑疾 病干预领域的广泛应用，同时为我国高端科研仪器自主可控提供强有力的支撑。 近日，北京超维景生物科技有限公司（以下简称"超维景"）宣布完成超亿元B+轮融资。本轮融资由广东中医药大健康 基金、北京市医药健康产业投资基金、中关村科学城投资公司、海开控股集团、天津合盈海河脑机基金等五家具备深 厚产业背景的投资机构联合投资。 （超维景公众号） ...

Group 1 - The core viewpoint of the article is that Eli Lilly announced its intention to acquire biotechnology company Orna Therapeutics for up to $2.4 billion in cash to strengthen its position in the autoimmune sector [1] Group 2 - Orna Therapeutics' main candidate drug, ORN-252, is aimed at treating B cell-driven autoimmune diseases and is currently in the early stages of development [1]

Core Viewpoint - Eli Lilly announced the acquisition of biotechnology company Orna Therapeutics for up to $2.4 billion in cash, focusing on the development of ORN-252, a candidate drug aimed at treating B cell-driven autoimmune diseases currently in early-stage development [1] Group 1 - Eli Lilly is acquiring Orna Therapeutics for a total cash consideration of up to $2.4 billion [1] - Orna Therapeutics' main candidate drug, ORN-252, targets B cell-driven autoimmune diseases [1] - The drug ORN-252 is currently in the early stages of development [1]